Biotech | April 25, 2022
‘DREAM-ND’ and ‘DREAM-D’ Phase 3 trials of Desidustat published in American Journal of Nephrology
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
It is a multi-speciality healthcare brand which delivers a hassle-free experience for all types of cosmetic procedures and elective surgeries with personalized care
Real-world evidence from more than 850,000 hospitalized patients provides clinical insights on the use of Veklury (remdesivir) as stand of care Covid-19 treatment
Erytech is evaluating valuable strategic options to leverage its Erycaps platform and its development and manufacturing capabilities with complementary assets and/or a broader corporate transaction
April 25th is commemorated as World Malaria Day
Deputy Mayor from Addis Ababa (Ethiopia) battled out a rare laryngeal cancer at Yashoda Hospitals Hyderabad
Heavy bleeding after giving birth is globally a leading cause of death in new mothers
If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe
With one of the most diverse lung cancer development programs, Novartis is focused on investments to advance the science, drive treatment and make an impact on patients
Subscribe To Our Newsletter & Stay Updated
